Ashton Thomas Private Wealth LLC Raises Position in Abbott Laboratories $ABT

Ashton Thomas Private Wealth LLC boosted its holdings in Abbott Laboratories (NYSE:ABT) by 10.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 55,630 shares of the healthcare product maker’s stock after purchasing an additional 5,356 shares during the period. Ashton Thomas Private Wealth LLC’s holdings in Abbott Laboratories were worth $7,451,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ABT. Carr Financial Group Corp increased its stake in Abbott Laboratories by 2.0% in the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after purchasing an additional 76 shares during the period. Tortoise Investment Management LLC increased its stake in shares of Abbott Laboratories by 10.7% in the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after buying an additional 77 shares during the period. Gemmer Asset Management LLC raised its holdings in Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after buying an additional 78 shares during the last quarter. Bridgewater Advisors Inc. boosted its position in Abbott Laboratories by 0.6% during the 2nd quarter. Bridgewater Advisors Inc. now owns 12,555 shares of the healthcare product maker’s stock valued at $1,607,000 after buying an additional 79 shares during the period. Finally, Nia Impact Advisors LLC grew its holdings in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after acquiring an additional 79 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $108.95 on Wednesday. The business’s fifty day moving average is $122.03 and its 200 day moving average is $127.24. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The stock has a market cap of $189.45 billion, a price-to-earnings ratio of 29.29, a PEG ratio of 1.74 and a beta of 0.75. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ABT. Argus lowered their price objective on shares of Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Oppenheimer lowered their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Piper Sandler dropped their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. The Goldman Sachs Group reduced their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Finally, Daiwa Capital Markets dropped their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s CEO made a roughly $2M insider purchase, signaling management’s confidence in the stock amid the pullback; insider buying can support sentiment and is often viewed as a bullish sign by investors. Read More.
• Positive Sentiment: Freedom Capital upgraded ABT to a “Buy,” adding demand-side support from at least one asset manager which can temper downside and attract buyers looking for upgrades. Read More.
• Positive Sentiment: Long-term bullish analysts and dividend-growth commentators highlight Abbott’s Dividend Aristocrat status, strong cash flow and multi-year revenue growth — a reminder of the stock’s longer-term appeal to income and total-return investors. Read More.
• Neutral Sentiment: Abbott’s tie-up with Exact Sciences reshapes its diagnostics footprint even as it signals a strategic pivot; investors will watch integration progress and whether diagnostics can offset nutrition weakness. This is strategically important but will take time to affect results. Read More.
• Neutral Sentiment: Analyst commentary is mixed — some bullish takes and value comparisons (e.g., relative to peers) keep the long-term case alive but do not remove near-term execution risks. Read More.
• Negative Sentiment: FDA is scrutinizing the FreeStyle Libre system and broader quality controls, raising regulatory and remediation risk that could affect device revenue, recall costs or approval timelines — a clear near-term negative for investor sentiment. Read More.
• Negative Sentiment: Abbott warned of profit pressure after missing revenue estimates; pediatric nutrition remains under sustained pressure, which is the primary near-term drag on revenue and margins. Continued weakness in that division is a key reason earnings guidance was tempered. Read More.
• Negative Sentiment: Several brokerages cut price targets recently (Barclays lowered its target to $142 though kept an overweight rating; Daiwa and Leerink trimmed targets to $113 and $119), increasing short-term selling pressure by reducing upside expectations and signaling cautious near-term forecasts. Read More. Read More. Read More.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.